1. Home
  2. UI vs ARGX Comparison

UI vs ARGX Comparison

Compare UI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UI
  • ARGX
  • Stock Information
  • Founded
  • UI 2003
  • ARGX 2008
  • Country
  • UI United States
  • ARGX Netherlands
  • Employees
  • UI N/A
  • ARGX N/A
  • Industry
  • UI Radio And Television Broadcasting And Communications Equipment
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • UI Technology
  • ARGX Health Care
  • Exchange
  • UI Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • UI 44.5B
  • ARGX 51.1B
  • IPO Year
  • UI 2011
  • ARGX 2017
  • Fundamental
  • Price
  • UI $610.00
  • ARGX $847.81
  • Analyst Decision
  • UI Buy
  • ARGX Strong Buy
  • Analyst Count
  • UI 2
  • ARGX 17
  • Target Price
  • UI $509.50
  • ARGX $866.53
  • AVG Volume (30 Days)
  • UI 201.2K
  • ARGX 373.7K
  • Earning Date
  • UI 11-07-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • UI 0.42%
  • ARGX N/A
  • EPS Growth
  • UI 103.15
  • ARGX N/A
  • EPS
  • UI 11.76
  • ARGX 23.27
  • Revenue
  • UI $2,573,545,000.00
  • ARGX $3,683,281,000.00
  • Revenue This Year
  • UI $13.66
  • ARGX $85.93
  • Revenue Next Year
  • UI $8.55
  • ARGX $35.17
  • P/E Ratio
  • UI $64.59
  • ARGX $33.96
  • Revenue Growth
  • UI 33.45
  • ARGX 92.98
  • 52 Week Low
  • UI $249.94
  • ARGX $510.06
  • 52 Week High
  • UI $803.60
  • ARGX $855.70
  • Technical
  • Relative Strength Index (RSI)
  • UI 34.20
  • ARGX 67.63
  • Support Level
  • UI $733.65
  • ARGX $812.79
  • Resistance Level
  • UI $790.00
  • ARGX $850.66
  • Average True Range (ATR)
  • UI 36.18
  • ARGX 23.94
  • MACD
  • UI -14.11
  • ARGX -1.22
  • Stochastic Oscillator
  • UI 1.68
  • ARGX 93.41

About UI Ubiquiti Inc.

Ubiquiti Inc is a seller of equipment and provides the related software platforms through web stores. The group develops technology platforms for high-capacity distributed Internet access, unified information technology, and consumer electronics for professional, home, and personal use. Its solutions are: high-performance networking technology for enterprises, service providers, and consumers. target the enterprise and service provider markets through a community of service providers, distributors, value-added resellers, webstores, systems integrators, and corporate IT professionals, which it refers to as the Ubiquiti Community. It targets consumers through digital marketing, including through webstores, retail chains, and, to a lesser extent, the Ubiquiti Community.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: